Financial Survey: Black Titan (BTTC) versus Its Competitors

Black Titan (NASDAQ:BTTC) is one of 48 public companies in the “Services – Computer Programming And Data Processing” industry, but how does it weigh in compared to its rivals? We will compare Black Titan to similar businesses based on the strength of its earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Earnings and Valuation

This table compares Black Titan and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$180,000.00	-$4.71 million	-0.58
Black Titan Competitors	$233.35 million	-$56.06 million	-10.88

Black Titan’s rivals have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

57.9% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 53.7% of Black Titan shares are held by insiders. Comparatively, 20.6% of shares of all “Services – Computer Programming And Data Processing” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Black Titan has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s rivals have a beta of 0.54, suggesting that their average stock price is 46% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Black Titan and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	96	199	216	13	2.28

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 127.94%. Given Black Titan’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Black Titan has less favorable growth aspects than its rivals.

Profitability

This table compares Black Titan and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-37.79%	-997.78%	-64.21%

Summary

Black Titan rivals beat Black Titan on 7 of the 13 factors compared.

Black Titan Company Profile

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.